Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dynavox Group ABFRA:H3Q -2.47%81 5-Year Yield-on-Cost % is 0.68 as of Aug. 10, 2026, which is 7% below its 10-year median of 0.73. GuruFocus rates FRA:H3Q with a GF Score™ of 81/100 and a GF Value™ of €7.90 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 318 Medical Devices & Instruments companies, Dynavox Group AB ranks worse than 83.65% on this metric.
Dynavox Group AB's yield on cost for the quarter that ended in Jun. 2026 was 0.68.
The historical rank and industry rank for Dynavox Group AB's 5-Year Yield-on-Cost % or its related term are showing as below:
FRA:H3Q'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.68 Med: 0.73 Max: 0.78
Current: 0.68
During the past 7 years, Dynavox Group AB's highest Yield on Cost was 0.78. The lowest was 0.68. And the median was 0.73.
FRA:H3Q's 5-Year Yield-on-Cost % is ranked worse than 83.65% of 318
companies
in the Medical Devices & Instruments industry
Industry Median: 2.355
vs FRA:H3Q: 0.68
Dynavox Group AB (FRA:H3Q) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Dynavox Group AB 5-Year Yield-on-Cost % Related Terms
FRA:H3Q vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, Dynavox Group AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dynavox Group AB 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Dynavox Group AB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Dynavox Group AB's 5-Year Yield-on-Cost % falls into.
Dynavox Group AB 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Dynavox Group AB (FRA:H3Q) has a 5-Year Yield-on-Cost % of 0.68 as of Aug. 10, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dynavox Group AB and its competitors. This is near median its historical median of 0.73. Over the past decade, Dynavox Group AB's 5-Year Yield-on-Cost % has ranged from 0.68 to 0.78. According to the industry distribution chart, Dynavox Group AB ranks #266 out of 318 companies in the Medical Devices & Instruments industry, placing it in the top 83.6%.
Is Dynavox Group AB's 5-Year Yield-on-Cost % too high?
Dynavox Group AB's current 5-Year Yield-on-Cost % of 0.68 is near median its 10-year median of 0.73. Over the past 10 years, this metric has ranged from a low of 0.68 to a high of 0.78. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.36. Dynavox Group AB's value of 0.68 is 71.1% below this industry median. Based on the distribution chart, Dynavox Group AB ranks #266 out of 318 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Dynavox Group AB has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dynavox Group AB's 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Dynavox Group AB ranks #266 out of 318 companies for 5-Year Yield-on-Cost %. This places Dynavox Group AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.36. Dynavox Group AB's value of 0.68 is 71.1% below this benchmark. Historically, Dynavox Group AB's own 5-Year Yield-on-Cost % has ranged from 0.68 to 0.78 over the past decade. While the company's 10-year median is 0.73 vs. the industry median of 2.36, Dynavox Group AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.36, based on 318 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dynavox Group AB's current 5-Year Yield-on-Cost % of 0.68 is 71.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Dynavox Group AB and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dynavox Group AB's current 5-Year Yield-on-Cost % is 0.68, which is near median its own 10-year median of 0.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dynavox Group AB stock overvalued right now?
Based on GuruFocus' analysis, Dynavox Group AB (FRA:H3Q) is currently considered Modestly Undervalued. The stock's GF Value™ is €7.90, compared to a current price of €6.72 — trading 14.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.68, which is near median its 10-year median of 0.73 and 71.1% below the Medical Devices & Instruments industry median of 2.36. Dynavox Group AB's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Dynavox Group AB (FRA:H3Q), the current 5-Year Yield-on-Cost % is 0.68 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dynavox Group AB (FRA:H3Q) Overvalued in 2026?
Based on GuruFocus' analysis, Dynavox Group AB stock appears to be undervalued.
The current stock price of €6.72 is trading 14.9% below its estimated GF Value™ of €7.90.
GuruFocus considers Dynavox Group AB to be Modestly Undervalued.
Key valuation signals for FRA:H3Q:
5-Year Yield-on-Cost %: 0.68 (near median its 10-year median of 0.73)
GF Value™: €7.90 vs. price of €6.72 (14.9% below fair value)
Industry Position: 71.1% below the Medical Devices & Instruments median (#266 of 318)
No single metric tells the full story. See the FRA:H3Q stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dynavox Group AB is engaged in assistive technology for communication. The company's Augmentative and Alternative Communication (AAC) solutions enable people with disabilities such as cerebral palsy, ALS, and spinal cord injury to communicate with a voice of their own, develop literacy skills, and live more independently. The company is a comprehensive SaaS provider with local roots. The company operates in Europe, North America, and Other countries, with the majority of revenue from North America.
81GF Score
Get the complete analysis for FRA:H3Q
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:H3Q has been successfully added to your 
